A carregar...
CAR T-cell product performance in haematological malignancies before and after marketing authorisation
Chimeric antigen receptor (CAR) T cells represent a potent new approach to treat haematological malignancies. Two CAR T-cell therapies, tisagenlecleucel and axicabtagene ciloleucel, have been approved in Europe and the USA, as well as several other countries, for the treatment of leukaemia and lymph...
Na minha lista:
| Publicado no: | Lancet Oncol |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7841982/ https://ncbi.nlm.nih.gov/pubmed/32007196 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(19)30729-6 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|